Loading provider…
Loading provider…
Hematology & Oncology Physician in New York, NY
NPI: 1114192242Primary Employer
Mskcc Clinical Practice Plan
mskcc.org
HQ Phone
Get MD Doris's Phone NumberMobile
Get MD Doris's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
FL State Medical License
2022
NJ State Medical License
2021 - 2025
NY State Medical License
2008 - 2025
PA State Medical License
2002 - 2005

American Board of Internal Medicine
Hematology
Westchester Medical Center
Fellowship • Hematology and Medical Oncology
2005 - 2008
Albert Einstein Healthcare Network
Residency • Internal Medicine
2002 - 2005
Central University of Venezuela
Medical School
Until 1999
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 35 | 118 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 34 | 62 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 32 | 186 |
Authors: Richard O'Reilly, Nancy Kernan, Craig Sauter, Miguel Perales, Katharine Hsu, Andromachi Scaradavou, Robert Jenq, Alan Hanash, Marcel Van Den Brink, Susan Prockop, Sergio Giralt, Juliet Barker, James Young
Journal: Blood
Publication Date: 2014-11-06
Authors: Susan Dewolf, Amanda Blouin, Miguel Perales, Roni Tamari, Robert Jenq, Alan Hanash, Maria Arcila, Rajmohan Murali, Jonathan Peled, Sergio Giralt, Ioannis Politikos
Journal: Sci Transl Med
Publication Date: 2023-07-26
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Intervention / Treatment: DEVICE: Photobiomodulation Therapy, OTHER: Placebo sham device
Lead Sponsor: Adienne SA
Collaborators: ADIENNE S.r.l. S.U.
Intervention / Treatment: BIOLOGICAL: Begelomab, BIOLOGICAL: Conventional Second-line Treatment
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: Millennium: The Takeda Oncology Company
Intervention / Treatment: DRUG: Ixazomib